Thinking about picking up some Merck KGaA shares, but wondering if the current price tag does the business justice? You're not alone. Value hunters and long-term investors keep asking the same ...

Merck (MRK) stock fell over 2% in premarket trading as the company's ... earnings call transcript before the market opens on ...

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.

Among the Nasdaq-100 index stocks, GlobalFoundries GFS and Lam Research LRCX rallied around 3% apiece, making them some of ...

Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Merck reported Q3 2025 revenue of $17.3 billion and adjusted EPS of $2.58, both above expectations, and raised its full-year ...

North American Morning Briefing: Stock Futures Fall as Investors Digest Tech Earnings, Trump-Xi Meeting Stock futures pointed lower early Thursday, as investors tried to make sense of a mixed bag of ...

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to ...

Keytruda remains a major growth driver, with Q2 revenue up 9% year over year, but its looming loss of exclusivity is ...